New York, January 28, 2014 -- Moody's Investors Service said that Catalent Pharma Solutions, Inc.'s (Catalent) announced plan for an initial public offerings (IPO) is credit positive. However, Catalent's ratings including its B2 Corporate Family Rating and negative rating outlook are unaffected by the announcement.
Vollständigen Artikel bei Moodys lesen